Efficacy and Safety of Switching from Enfuvirtide to Raltegravir in Patients with Virological Suppression

REFERENCES

• Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348:2175–2185.
   PubMed Web of Science ®Google Scholar
• Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003;348:2186–2195.
   PubMed Web of Science ®Google Scholar
• Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359:339–354.
   PubMed Web of Science ®Google Scholar
• Raffi F, Battegay M, Rusconi S, et al. Combined tipranavir and enfuvirtide use associated with higher plasma tiprana-vir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST. AIDS. 2007;21:1977–1980.
   PubMed Web of Science ®Google Scholar
• Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet. 2006;368:466–475.
   PubMed Web of Science ®Google Scholar
• Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:29–38.
   PubMed Web of Science ®Google Scholar
• Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:39–48.
   PubMed Web of Science ®Google Scholar
• Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359:1429–1441.
   PubMed Web of Science ®Google Scholar
• Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS. 2007;21:395–402.
   PubMed Web of Science ®Google Scholar
• Makinson A, Reynes J. The fusion inhibitor enfuvirtide in recent antiretroviral strategies. Curr Opin HIV AIDS. 2009;4:150–158.
   PubMed Web of Science ®Google Scholar
• DeJesus E, Gottlieb MS, Gathe JC Jr, et al. Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study. Antimicrob Agents Chemother 2008;52:4315–4319.
   PubMed Web of Science ®Google Scholar
• Harris M, Larsen G, Montaner JS. Outcomes of multi-drug-resistant patients switched from enfuvirtide to ralte-gravir within a virologically suppressive regimen. AIDS. 2008;22:1224–1226.
   PubMed Web of Science ®Google Scholar
• Sayana S, Prosser P, Ricaurte JC, et al. Analysis of a switch from enfuvirtide to raltegravir in patients with unde-tectable viral load: efficacy and quality of life at 24 weeks. J Int Assoc Physicians AIDS Care. 2009;8:85–86.
   Google Scholar
• Talbot A, Machouf N, Thomas R, et al. Retrospective anal-ysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and safety at 12 weeks in a Montreal Cohort. Presented at: 17th Interna-tional AIDS Conference; August 3–8, 2008; Mexico City, Mexico. Abstract TUPE0112.
   Google Scholar
• De Castro N, Braun J, Charreau I, et al. Switch from enfu-virtide (E) to raltegravir (R) in highly treatment-experienced HIV-1 infected patients: a randomized open-label non-inferiority trial (Easier - ANRS 138). In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections; February 8–11, 2009; Montreal. Abstract 572.
   Google Scholar
• Towner W, Klein D, Kerrigan HL, et al. Virologic outcomes of changing Enfuvirtide to Raltegravir in HIV-1 patients well controlled on an Enfuvirtide based regimen: 24-week results of the CHEER Study. J Acquir Immune Defic Syndr 2009;51:367–373.
   PubMed Web of Science ®Google Scholar
• Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359:355–365.
   PubMed Web of Science ®Google Scholar
• Lennox J, Dejesus E, Lazzarin A, et al. STARTMRK, A Phase III study of the safety & efficacy of raltegravir (RAL)-based vs efavirenz (EFV)-based combination therapy in treatment-naive HIV-infected patients. In: Program and abstracts of the 48th International Conference on Antimi-crobial Agents and Chemotherapy (ICAAC 2008); October 25–28, 2008; Washington, DC. Abstract H–896a.
   Google Scholar
• Anderson MS, Sekar V, Tomaka F, et al. Pharmacokinetic (PK) evaluation of darunavir/ritonavir (DRV/r) and ralte-gravir in healthy subjects. Presented at: 48th Annual ICAAC / IDSA 46th Annual Meeting; October 25–28, 2008; Washington, DC.
   Google Scholar
• Florence E, De Wit S, Castagna A, et al. Antiretroviral treatment use and HIV-RNA suppression rates for 941 European patients in the etravirine expanded access programme. Presented at: 9th International Congress on Drug Therapy in HIV Infection; November 9–13, 2008; Glasgow, UK.
   Google Scholar
• Kerrigan H, Towner W, Klein D, et al. Treatment response among HIV patients co-enrolled in the etravirine (ETR) and raltegravir (RAL) expanded access programs (EAPs) at Kaiser Permanente. Presented at: ICAAC 48th Annual ICAAC / IDSA 46th Annual Meeting; October 25–28, 2008; Washington, DC.
   Google Scholar
• Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic success with raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: results of the ANRS 139 TRIO trial. Presented at: 17th International AIDS Conference; August 3–8, 2008; Mexico City, Mexico.
   Google Scholar
• Khanlou H, Allavena C, Billaud E, et al. Development of hepatic cytolysis after switching from enfuvirtide to raltegravir in virologically suppressed patients treated with tipranavir/ritonavir. Presented at: 17th International AIDS Conference; August 3–8, 2008; Mexico City, Mexico. Poster A-072-0082-07276 232.
   Google Scholar
• Ribera E, Loutfy M, Florence E, et al. Switching from enfu-virtide to etravirine — efficacy results from the etravirine early access programme. Presented at: 9th International Congress on Drug Therapy in HIV Infection; November 9–13, 2008; Glasgow, UK.
   Google Scholar